This month’s candidate, Nanosphere (NSPH), has developed a breakthrough technology for advanced molecular diagnostic testing. Its Verigene System is already approved, providing time-critical diagnosis for early detection of diseases and timely treatment of patients. And the company’s yet-to-be-approved Troponin test diagnoses heart attack risk, an enormous market. NSPH is currently priced under 1.50, but I think the stock is fairly valued at 2.50. Open up your issue now and read all the details on Nanosphere and all our current stock recommendations.
